5 results
The primary objective of this study is to evaluate the proportion of patients achieving FXI inhibition * 80% at trough (Day 91) after monthly dosing at 3 dose levels of MAA868.
To determine the within and between variability of pharmacokinetic (PK) profiles in patients treated with DOACs in daily practice
Lu AF28996 is an orally administered investigational compound of a potent, long-acting dopamine agonist, Lu AA40326, currently under development by H. Lundbeck A/S for the treatment of Parkinson*s disease (PD). Primary Objective:to investigate the…
The primary objectives of this study are:* Analyse if shear wave ultrasound elastography with ElastQ and LASTIC are both feasible techniques to identify differences in tongue tissue elasticity and analyse if there is a correlation between both…
To measure DOAC levels just before surgery of all DOAC patients in the LUMC with elective surgery for which ceasing of DOAC treatment is required.